FDA highlights new tech to monitor trials

The FDA is encouraging drug developers to turn to new technology to help them monitor clinical trial work without resorting to frequent site visits, according to a report in Outsourcing-Pharma. In a new set of proposed guidelines, regulators specifically cited electronic data capture and statistical assessments to help them monitor the quality of the studies they sponsor. But no company, regulators add, should call a halt to their on-site visits. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.